Tyler Z. Gillingham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tyler Z. Gillingham has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Beckmann
The University of Texas MD Anderson Cancer Center 3 The Neurodegeneration Consortium, Therapeutics Discovery Division Houston, TX, USA
1 shared publication - Alison E. Mungenast
Picower Institute for Learning and Memory, Massachusetts Institute of Technology 1 Department of Brain and Cognitive Sciences Cambridge, MA, USA
1 shared publication - Alison M. Goate
Icahn School of Medicine at Mount Sinai
1 shared publication - Anne Schaefer
Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, USA
1 shared publication - Barbara Czako
The University of Texas MD Anderson Cancer Center 3 The Neurodegeneration Consortium, Therapeutics Discovery Division Houston, TX, USA
1 shared publication - Carmen Romero-Molina
Icahn School of Medicine at Mount Sinai
1 shared publication
Latest Publications
- Open Access
- 29 August 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (11)
A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation
Pervasive neuroinflammation occurs in many neurodegenerative diseases, including Alzheimer’s disease (AD). SPI1/PU.1 is a transcription factor located at a genome-wide significant AD-risk locus and its reduced expression is associated with delayed onset of AD. We analyzed single-cell transcriptomic datasets from microglia of human AD patients and found an enrichment of PU.1-binding motifs in the differentially expressed genes. In hippocampal tissues from transgenic mice with neurodegeneration, we found vastly increased genomic PU.1 binding. We then screened for PU.1 inhibitors using a PU.1 reporter cell line and discovered A11, a molecule with anti-inflammatory efficacy and nanomolar potency. A11 regulated genes putatively by recruiting a repressive complex containing MECP2, HDAC1, SIN3A, and DNMT3A to PU.1 motifs, thus representing a novel mechanism and class of molecules. In mouse models of AD, A11 ameliorated neuroinflammation, loss of neuronal integrity, AD pathology, and improved cognitive performance. This study uncovers a novel class of anti-inflammatory molecules with therapeutic potential for neurodegenerative disorders.
- 29 August 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (11)
Open AccessA novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation
Pervasive neuroinflammation occurs in many neurodegenerative diseases, including Alzheimer’s disease (AD). SPI1/PU.1 is a transcription factor located at a genome-wide significant AD-risk locus and its reduced expression is associated with delayed onset of AD. We analyzed single-cell transcriptomic datasets from microglia of human AD patients and found an enrichment of PU.1-binding motifs in the differentially expressed genes. In hippocampal tissues from transgenic mice with neurodegeneration, we found vastly increased genomic PU.1 binding. We then screened for PU.1 inhibitors using a PU.1 reporter cell line and discovered A11, a molecule with anti-inflammatory efficacy and nanomolar potency. A11 regulated genes putatively by recruiting a repressive complex containing MECP2, HDAC1, SIN3A, and DNMT3A to PU.1 motifs, thus representing a novel mechanism and class of molecules. In mouse models of AD, A11 ameliorated neuroinflammation, loss of neuronal integrity, AD pathology, and improved cognitive performance. This study uncovers a novel class of anti-inflammatory molecules with therapeutic potential for neurodegenerative disorders.